Anthropic IPO Marketing Expected to Start in Mid-October 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Milei Threatens Falkland Oil Firms With Sanctions 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Add as a preferred source on Google
Geneva, Switzerland and Boston, MA - February 23, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will release the top line results from the IMPLANT2 clinical trial of its oxytocin receptor antagonist, Nolasiban, which is being developed for improving pregnancy rate following in vitro fertilization (IVF/ICSI) procedures, on the morning of Monday February 26, 2018. ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, on February 26, 2018 to discuss these results.
Investors may participate by dialing +1(844) 419-1772 for U.S. callers and +1(213) 660-0921 for international callers, and referring to conference ID 9784807. The webcast can be accessed under the "Investors" section of ObsEva's website www.obseva.com
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
CEO Office contact:
Shauna Dillon
[email protected]
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
[email protected]
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/875bf795-85d0-4113-b453-10a7f908f49c
